 Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

Ibrahim Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the impact of enhanced lymphodepletion on response rates and infection severity with the allogeneic CAR-T cell therapy WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic leukemia (LBL) in a phase 1/2 trial (NCT04984356).

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


European Hematology Association Congress

City of Hope

Cancer Centers

Partner

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.